Search Browse Earnings

SAB Biotherapeutics, Inc. — SlamSEC

SAB Biotherapeutics, Inc.

Nasdaq:SABSNasdaq:SABSW

Biological Products, (No Diagnostic Substances)·MIAMI BEACH, FL

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$2.2M

-90.6% YoY

FY 2024

Adj. EBITDA

-$34.4M

-1537.4% margin

FY 2024

Net Income

-$42.2M

-1884.5% margin

FY 2024

EPS (Diluted)

-$7.64

FY 2024

Stock Price

$3.81

+0.0%

2026-03-09

52W Range

$1.00 – $6.60

P/E Ratio

-0.5x

Market Cap

$181.1M

Cash

$56.6M

FY 2024

Total Debt

$1.1M

FY 2024

Net Cash

$55.5M

FY 2024

Enterprise Value

$125.6M

Debt / EBITDA

1.6x

FY 2024

EV / EBITDA

-3.6x

Employees

—